Targeted protein degradation as an antiviral approach

Area of Science:

• Biochemistry
• Pharmacology
• Drug Discovery

Background:

• Targeted protein degradation (TPD) is an emerging drug discovery modality.
• TPD utilizes small molecules to induce the degradation of target proteins.
• This mechanism contrasts with traditional direct-acting antivirals (DAAs) that inhibit protein activity.

Purpose of the Study:

• To review the pharmacology of TPD.
• To outline the current tools for developing TPD-based antiviral small molecules.
• To highlight TPD's potential advantages for antiviral drug development.

Main Methods:

• Review of existing literature on TPD pharmacology.
• Analysis of current tools and technologies for TPD small molecule development.
• Discussion of TPD's unique pharmacological properties in the context of antiviral therapy.

Main Results:

• TPD exhibits event-driven pharmacology, differing from the occupancy-driven pharmacology of DAAs.
• This mechanistic difference can lead to distinct drug efficacy and pharmacodynamics.
• TPD is widely used in cancer and autoimmune diseases but underexplored for antiviral applications.

Conclusions:

• TPD presents a promising, yet underutilized, strategy for developing novel antiviral agents.
• The unique pharmacological profile of TPD may overcome limitations of current antiviral therapies.
• Further research into TPD-based antivirals is encouraged to expand the antiviral armamentarium.